Related Experiment Video
Updated: Feb 27, 2026
Selection of Aptamers for Amyloid β-Protein, the Causative Agent of Alzheimer's Disease
Published on: May 13, 2010
Selective targeting of primary and secondary nucleation pathways in Aβ42 aggregation using a rational antibody
Francesco A Aprile1, Pietro Sormanni1, Michele Perni1
1Centre for Misfolding Diseases, Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, UK.
Abstract:
Antibodies targeting Aβ42 are under intense scrutiny because of their therapeutic potential for Alzheimer's disease. To enable systematic searches, we present an "antibody scanning" strategy for the generation of a panel of antibodies against Aβ42. Each antibody in the panel is rationally designed to target a specific linear epitope, with the selected epitopes scanning the Aβ42 sequence. By screening in vitro the panel to identify the specific microscopic steps in the Aβ42 aggregation process influenced by each antibody, we identify two antibodies that target specifically the primary and the secondary nucleation steps, which are key for the production of Aβ42 oligomers. These two antibodies act, respectively, to delay the onset of aggregation and to block the proliferation of aggregates, and correspondingly reduce the toxicity in a Caenorhabditis elegans model overexpressing Aβ42. These results illustrate how the antibody scanning method described here can be used to readily obtain very small antibody libraries with extensive coverage of the sequences of target proteins.
Insights
Researchers developed an antibody scanning strategy to create antibodies targeting amyloid-beta 42 (Aβ42) for Alzheimer's disease therapy. Two antibodies effectively inhibited Aβ42 aggregation and reduced toxicity in a model organism.
Area of Science:
- Neuroscience
- Immunology
- Biochemistry
Background:
- Alzheimer's disease (AD) is a neurodegenerative disorder characterized by the aggregation of amyloid-beta 42 (Aβ42) peptides.
- Antibodies targeting Aβ42 are a promising therapeutic strategy for AD, but require precise epitope targeting.
- Systematic generation and screening of antibodies are crucial for identifying effective therapeutic candidates.
Purpose of the Study:
- To develop an "antibody scanning" strategy for generating a panel of antibodies against Aβ42.
- To identify antibodies that specifically target key steps in the Aβ42 aggregation process.
- To evaluate the therapeutic potential of identified antibodies in reducing Aβ42 toxicity.
Main Methods:
- Generation of an antibody panel using an "antibody scanning" strategy, with each antibody targeting a specific linear epitope of Aβ42.
- In vitro screening of the antibody panel to identify antibodies influencing specific microscopic steps of Aβ42 aggregation.
- Assessment of antibody efficacy in a *Caenorhabditis elegans* model overexpressing Aβ42.
Main Results:
- Identified two antibodies that specifically target primary and secondary nucleation steps in Aβ42 aggregation.
- One antibody delayed aggregation onset, while the other blocked aggregate proliferation.
- Both antibodies significantly reduced Aβ42-induced toxicity in the *C. elegans* model.
Conclusions:
- The "antibody scanning" method enables efficient generation of small, comprehensive antibody libraries against target proteins like Aβ42.
- Targeting specific nucleation steps of Aβ42 aggregation with antibodies holds therapeutic potential for Alzheimer's disease.
- This strategy facilitates the discovery of antibodies with distinct mechanisms of action against amyloid pathology.
More Related Videos
06:17A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
Published on: May 22, 2018
13:31Novel Atomic Force Microscopy Based Biopanning for Isolation of Morphology Specific Reagents against TDP-43 Variants in Amyotrophic Lateral Sclerosis
Published on: February 12, 2015